Autophagy is a cellular mechanism to degrade damaged organelles, cell membranes and proteins, and the failure of autophagy is thought to be one of the main reasons for the accumulation of cell damage and aging. Autophagy is turned on when cell chooses to survive against external and internal stresses through energy regeneration and cellular homeostasis. Autophagy is being studied globally to introduce new paradigms for treatment of metabolic diseases and autoimmune diseases.
Incospharm Corporation is constructing novel natural and peptide autophagy inducer libraries to provide potential therapeutic solutions for the treatment of metabolic diseases and autoimmune diseases.
Incospharm’s autophagy inducers are being tested against metabolic diseases such as diabetes type 2, Alzheimer’s disease, Parkinson’s disease, where toxic oligomers (hIAPP, beta-amyloid, synulein) accumulation leads to cell death and related diseases.